NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)
announced today that it has opted not to proceed with the public offering of units of the Company announced on April 17, 2018,
based on the Company’s assessment that market conditions are not currently conducive for a public offering on terms that would be
in the best interests of the Company and its shareholders.
Resverlogix intends instead to carry out financing options that the Company has been pursuing that are more
favourable to the Company.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing
genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition
of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk
cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and
low high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations
Email:ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact, including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward looking information relating to the Company’s intention to carry out
financings and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal
disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases.
Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information
Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The
forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
